Alpha-Fetoprotein Tumor Marker (AFP)


AFP concentrations are increased in patients with liver cancer, hepatitis, and liver cirrhosis. Increased levels in severe hepatitis indicate liver cell regeneration. Thus, the absence of AFP in patients with fulminant hepatitis is considered a poor prognostic sign.

AFP concentrations decline to normal levels with effective therapy. Persistently elevated levels suggest residual disease; rising levels suggest disease progression or recurrence.

Clinical Use: Distinguishs between seminomatous and non-seminomatous testicular germ cell cancer. Monitors therapy and detect recurrence in individuals with non-seminomatous testicular germ cell cancer. Determines prognosis in individuals with fulminant hepatitis. Monitors therapy in individuals with hepatocellular carcinoma and monitors hepatitis B carriers for evidence of liver cancer

Alpha-Fetoprotein Tumor Marker (AFP)


Average competitors price


Pricing based on average direct to consumer pricing.
  • Fasting Required: No
  • Preferred Specimen:Serum
  • Reference Range(s):
      Male (ng/mL) Female (ng/mL)
    1 Month* 0.5-16387.0 0.5-18964.0
    1-11 Months* 0.5-28.3 0.5-77.0
    1-3 Years* 0.5-7.9 0.5-11.1
    3 Years 6.1 6.1
  • Limitations: Patients who have received monoclonal mouse antibodies may have abnormal results. For any patient taking a high dose of biotin, the specimen should be drawn at least eight hours after the last dose. The use of AFP as a tumor marker in pregnant females is not recommended. AFP is not recommended as a screening procedure to detect cancer in the general population.
  • For this test draws must be done: Mon-Fri 1st shift (cutoff 9 a.m.)
  • Turnaround Time: 3 days
  • Test Code: 237